UNITED LAB (03933) received a milestone payment of $13.5 million from Novonordisk for the exclusive licensing agreement for UBT251.
Federal Pharmaceutical (03933) announced that on July 15, 2026, Federal Biotechnology received a milestone payment of $13.5 million (after deducting the prepayment tax in Denmark) from Novo Nordisk for UBT251 injection targeting overweight or obesity indication in the global Phase I clinical trial.
United Lab (03933) announced that on July 15, 2026, Federal Biotech has received a milestone payment of $13.5 million (after deduction of prepayment taxes in Denmark) from Novo Nordisk for the UBT251 injection for overweight or obesity indications in global Phase I clinical trials.
Under the exclusive license agreement and subject to its terms and conditions, Federal Biotech is eligible to receive potential milestone payments of up to $1.8 billion, depending on the achievement of various development and sales milestones, as well as tiered sales royalties based on annual net sales in the region.
Related Articles
New stock outlook | The new car delivery exceeds one thousand vehicles, the actual operating mileage exceeds one billion, how far is Zero One Motors from profit?
JENSCARE-B(09877): The first group of subjects implanted with the LuX-ValvePlus transcatheter tricuspid valve replacement system have completed the key pivotal trial approved by the FDA.
SSY GROUP (02005): Procured drug production registration certificate for Fenobet Acid Choline Sustained-Release Capsules (135mg).
New stock outlook | The new car delivery exceeds one thousand vehicles, the actual operating mileage exceeds one billion, how far is Zero One Motors from profit?
JENSCARE-B(09877): The first group of subjects implanted with the LuX-ValvePlus transcatheter tricuspid valve replacement system have completed the key pivotal trial approved by the FDA.
SSY GROUP (02005): Procured drug production registration certificate for Fenobet Acid Choline Sustained-Release Capsules (135mg).
RECOMMEND
